Editorial: Biomarkers in head and neck cancer: genomic insights and nuclear medicine innovations

1

Biomarkers beyond clinical staging can predict treatment outcomes in head and neck cancer, including smoking history and genomic alterations.
2

PDL-1 expression is validated as a biomarker for immunotherapy response in recurrent/metastatic head and neck cancer.
3

The systemic immune inflammation nutrition score shows predictive value for overall survival in patients undergoing curative treatment.
4

Integrin alpha gene expression correlates with poor prognosis in head and neck squamous cell carcinoma, suggesting potential as prognostic biomarkers.
5

Future research should integrate various biomarkers to enhance treatment selection and individualization in head and neck cancer.

Frontiers In Medicine

1